Nexgenia, Inc.

Nexgenia produces proprietary reagents for molecular and cell separations. These reagents enable efficient, low cost, gentler separations of cells in blood.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Seattle, WA, US
  • Currency USD
  • Founded 2011
  • Employees 4
  • Website nexgeniacorp.com

Company Summary

Nexgenia develops and manufactures reagents based on proprietary technology licensed from the UW and developed internally. Nexgenia will sell these reagents to companies for use in their products or manufacturing. In particular Nexgenia intends to work with a limited number of biotechnology companies, enabling them to separate and isolate cells in the most efficient cost-effective manner possible. Nexgenia's is a business to business model.

Team

  • Ron Myers
    CEO

    Ron Myers was most recently chief legal officer and VP of strategic transactions at the Institute for Systems Biology in Seattle, WA. Myers was also the chief business officer at VLST Corp. and, prior to that, held executive positions at Corixa Corp., Invitrogen, and Pfizer. Ron has structured partnerships with companies in the bio therapeutic and biotech reagents markets. He currently serves on the Board of Directors of WBBA.

Advisors

Previous Investors

  • W Fund
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free